2024 Annual Meeting | C124 - Neurologic Complications of Checkpoint Inhibitors

Date Tuesday 04/16/24

Time 01:00 PM - 03:00 PM MDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Jorg Dietrich, MD, PhD, FAAN

Topic(s) Neuro-oncology

Learning Objectives Participants should gain an understanding of potential neurotoxic side effects of novel immunotherapies, including immune checkpoint inhibitors and CAR-T cells; learn to recognize clinical and imaging patterns of neurotoxicity after immunotherapy; and be able to discuss current management options and identify strategies designed to improve patient outcome.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice, Quality Improvement

Program Level Intermediate

Program Tracks Neurohospitalist

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation, Other

Program Evaluations

Event Timeline
01:00 PM - 01:30 PM MDT	Speaker	Immunotherapy Associated Complications: Case Presentations from Clinical Practice Amanda C. Guidon, MD
01:30 PM - 02:00 PM MDT	Speaker	Checkpoint Inhibitor-associated Peripheral Nervous System Complications Leonie Muller-Jensen, MD
02:00 PM - 02:30 PM MDT	Speaker	Checkpoint Inhibitor-associated Central Nervous System Complications James M. Hillis, MD
02:30 PM - 03:00 PM MDT	Speaker	CAR-T Cell Associated Neurologic Complications Jorg Dietrich, MD, PhD, FAAN

Faculty Disclosures
Jorg Dietrich, MD, PhD, FAAN	Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Therapeutics. Dr. Dietrich has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Johnson. Dr. Dietrich has received publishing royalties from a publication relating to health care.
Amanda C. Guidon, MD	An immediate family member of Dr. Guidon has received personal compensation for serving as an employee of GE Healthcare. Dr. Guidon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Guidon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Momenta. Dr. Guidon has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Guidon has received research support from MGFA. The institution of Dr. Guidon has received research support from Project Data Sphere. The institution of Dr. Guidon has received research support from MGNet. The institution of Dr. Guidon has received research support from MGNet. Dr. Guidon has received publishing royalties from a publication relating to health care.
Leonie Muller-Jensen, MD	Dr. Muller-Jensen has nothing to disclose.
James M. Hillis, MD	Dr. Hillis has stock in Elly Health. The institution of Dr. Hillis has received research support from GE Healthcare. The institution of Dr. Hillis has received research support from Annalise.ai. The institution of Dr. Hillis has received research support from Viz.ai. The institution of Dr. Hillis has received research support from Cerebriu. The institution of Dr. Hillis has received research support from Heuron. The institution of Dr. Hillis has received research support from JLK Group. Dr. Hillis has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��